Currently Viewing:
Newsroom
Currently Reading
Lack of Payer Support a Barrier to Diabetes Prevention, CDC Reports
December 17, 2017 – Mary Caffrey
Pfizer Announces Phase 3 Trial for Atopic Dermatitis Treatment
December 15, 2017 – Samantha DiGrande
Average Profit Margin on Oncology Drugs For 340B Hospitals Nears 50%
December 15, 2017 – Jaime Rosenberg
Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options
December 15, 2017 – Jaime Rosenberg
AJMC® in the Press, December 15, 2017
December 15, 2017 – AJMC Staff
What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts
December 15, 2017 – AJMC Staff
5 Key Takeaways From ASH 2017
December 15, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: December 15, 2017
December 15, 2017
What We're Reading: Medical Device Tax; Marijuana and Vaping; Birth Control Without Prescriptions
December 14, 2017 – AJMC Staff

Risk Factors for Neutropenia and Infections in Childhood ALL

AJMC Staff
A study published in the Annals of Oncology has analyzed data on young patients with acute lymphoblastic leukemia (ALL) to evaluate risk factors for febrile neutropenia and infection-related complications.
A study published in the Annals of Oncology has analyzed data on young patients with acute lymphoblastic leukemia (ALL) to evaluate risk factors for febrile neutropenia and infection-related complications.

Of the 2420 infection episodes seen in 409 children undergoing treatment for ALL, febrile neutropenia was seen in 1107 cases. The study found higher rates of neutropenia among patients with certain risk factor characteristics. A patient’s risk of neutropenia or infection also varied based on the stage of therapy, from the initial induction phase to the continuation phase.

Factors determining a patient’s risk group (low, standard, or high-risk) include age at diagnosis, initial white blood cell count, spread to other organs, and response to treatment. Clinicians use these risk groups to determine the intensity of treatment. Standard- and high-risk patients received more intensive therapy during the early continuation phase and had more incidences of neutropenia compared with low-risk patients. Age between 1 and 9.9 years at diagnosis was associated with febrile neutropenia in both the induction and later continuation phases of treatment. More intensive chemotherapy was also associated with higher rates of neutropenia.

The study also examined patient risk factors for infection-related complications. The most common type of infection among the 1313 episodes was upper respiratory, followed by ear, bloodstream, and gastrointestinal infections. Infections were most frequent during the induction or reinduction stages when patients undergo the most intensive chemotherapy treatment, but respiratory and ear infections were also seen during continuation phases.

The standard- and high-risk patients receiving more intensive therapy had higher incidences of infections. Age between 1 and 9.9 years at diagnosis was associated with infections during the later continuation phase of treatment. White race was associated with infection during the induction phase of treatment. A lack of neutrophil surge after dexamethasone treatment was associated with infections, as it can reflect the poor bone marrow reserve.

The study authors recommend that clinicians closely monitor children with these risk factors so they can be treated with antibiotics at the first sign of infection. Modifications to the chemotherapy regimen should also be considered for these at-risk patients. 

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!